The main purpose of this study is to characterize safety and to determine the recommended
phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to further assess the
safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Mantle Cell Lymphoma

Lymphoma

Blood Cancer

Hematologic Neoplasms

Hematologic Malignancies

Hematology

Hematological Malignancies

Refractory B-Cell NHL

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed B-cell NHL

JNJ-88998377

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical
(investigational or non-investigational) product. It does not necessarily have a causal
relationship with the investigational product.

Number of participant with DLT will be assessed. The DLTs are specific adverse events and
are defined as any of the following: high grade non-hematological or hematological
toxicity.

Plasma concentration of oral dose of JNJ-88998377 will be assessed.

Area under the plasma concentration versus time curve during a dosing interval (τ) at
steady-state concentration of JNJ-88998377 will be reported.

OR is defined as the percentage of participants who have a best response of partial
response (PR) or better per investigator assessment according to disease-specific
response criteria.

TTR is defined for participants who achieved a response of PR or better as the time from
the first dose of study treatment to the first response of PR or better per investigator
assessment according to disease-specific response criteria.

DOR is defined for participants who achieved a response of PR or better as the time
between the date of initial documentation of first response of PR or better to the date
of first documented evidence of progressive disease or death.

Participants will receive JNJ-88998377 at a selected starting dose. Subsequent dose
levels and schedules will be selected based on the review of all available data to
establish recommended Phase 2 dose (RP2D).

Participants will receive JNJ-88998377 at RP2D determined in Part A. Additional expansion
cohort(s) may be added with a lower RP2D(s), or different dose schedule(s) based on all
available data.

The main purpose of this study is to characterize safety and to determine the recommended
phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation) and to further assess the
safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Trials at a glance

Trials at a glance